Author:
Baltà-Foix Ricardo,Serrano-Adrover Caterina,López-Cano Adrià,Gifre-Renom Laia,Sanchez-Chardi Alejandro,Arís Anna,Garcia-Fruitós Elena
Abstract
Abstract
Background
Lactic Acid Bacteria such as Lactococcus lactis, Latilactobacillus sakei (basonym: Lactobacillus sakei) and Lactiplantibacillus plantarum (basonym: Lactobacillus plantarum) have gained importance as recombinant cell factories. Although it was believed that proteins produced in these lipopolysaccharides (LPS)-free microorganisms do not aggregate, it has been shown that L. lactis produce inclusion bodies (IBs) during the recombinant production process. These protein aggregates contain biologically active protein, which is slowly released, being a biomaterial with a broad range of applications including the obtainment of soluble protein. However, the aggregation phenomenon has not been characterized so far in L. plantarum. Thus, the current study aims to determine the formation of protein aggregates in L. plantarum and evaluate their possible applications.
Results
To evaluate the formation of IBs in L. plantarum, the catalytic domain of bovine metalloproteinase 9 (MMP-9cat) protein has been used as model protein, being a prone-to-aggregate (PTA) protein. The electron microscopy micrographs showed the presence of electron-dense structures in L. plantarum cytoplasm, which were further purified and analyzed. The ultrastructure of the isolated protein aggregates, which were smooth, round and with an average size of 250–300 nm, proved that L. plantarum also forms IBs under recombinant production processes of PTA proteins. Besides, the protein embedded in these aggregates was fully active and had the potential to be used as a source of soluble protein or as active nanoparticles. The activity determination of the soluble protein solubilized from these IBs using non-denaturing protocols proved that fully active protein could be obtained from these protein aggregates.
Conclusions
These results proved that L. plantarum forms aggregates under recombinant production conditions. These aggregates showed the same properties as IBs formed in other expression systems such as Escherichia coli or L. lactis. Thus, this places this LPS-free microorganism as an interesting alternative to produce proteins of interest for the biopharmaceutical industry, which are obtained from the IBs in an important number of cases.
Funder
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria
Ministerio de Ciencia, Innovación y Universidades
Agència de Gestió d'Ajuts Universitaris i de Recerca
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference64 articles.
1. Ferrer-Miralles N, Domingo-Espín J, Corchero J, Vázquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact. 2009;8:1–8.
2. Saccardo P, Corchero JL, Ferrer-Miralles N. Tools to cope with difficult-to-express proteins. Appl Microbiol Biotechnol Appl Microbiol Biotechnol. 2016;100:4347–55.
3. Gifre L, Arís A, Bach À, Garcia-Fruitós E. Trends in recombinant protein use in animal production. Microb Cell Fact. 2017;16:1–17.
4. European Medicines Agency. ICH guideline Q4B Annex 14 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on bacterial endotoxins tests – general Chap. 2013.
5. Gifre-Renom L, Cano-Garrido O, Fàbregas F, Roca-Pinilla R, Seras-Franzoso J, Ferrer-Miralles N, et al. A new approach to obtain pure and active proteins from Lactococcus lactis protein aggregates. Sci Rep. 2018;8:1–10.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献